Stereotactic vacuum-assisted breast biopsy in 2874 patients: a multicenter study.

BACKGROUND: Vacuum-assisted breast biopsy (VAB) can replace surgical biopsy for the diagnosis of breast carcinoma. The authors evaluated the accuracy and clinical utility of VAB in a multicenter setting using a strict quality assurance protocol. METHODS: In the current study, VABs were performed successfully for 2874 patients at 5 sites. Benign lesions were verified by follow-up. Surgery was recommended for malignant and borderline lesions. VAB was performed on patients with lesions rated as highly suspicious (6%), intermediate to suspicious (85%), or probably benign (9%). Fifty-eight percent of the lesions were < 10 mm and 70% had microcalcifications. RESULTS: The authors identified 7% of patients with invasive carcinomas, 15% with ductal carcinomas in situ (DCIS), 5% with atypical ductal hyperplasias (ADH), and 0.6% with lobular carcinomas in situ. The results of the VAB necessitated an upgrade of 24% of patients with ADH to DCIS or DCIS and invasive carcinoma. Twelve percent of patients with DCIS proved to have invasive carcinoma. Seventy-three percent of the patients had benign lesions. Only 1 false-negative result was encountered (negative predictive value, 99.95%). Minor side effects were reported to occur in 1.4% of patients and 0.1% of patients required a subsequent intervention. Scarring relevant for mammography was rare among patients (i.e., 0.3% of patients had relevant scarring). CONCLUSIONS: Quality-assured VAB was found to be highly reliable. VAB effectively identified patients with benign lesions and assisted therapeutic decisions. Most important, only a single case of malignancy was missed. A close interdisciplinary approach assured optimal results.

MR imaging of the contralateral breast in patients after breast-conserving therapy.

A study was undertaken to assess the diagnostic accuracy of contrast-enhanced MR mammography (MRM) of the contralateral breast in patients treated by breast-conserving therapy previously. A total of 119 patients underwent 145 standardized dynamic MR studies (1 T, T1-weighted 3D FLASH, 0.2 mmol Gd-DTPA/kg body weight). We retrospectively evaluated the results of conventional methods and MRM. A total of 11 contralateral carcinomas were present (detection rate 9%). The interval between treatment of the first primary and identification of contralateral malignancy was 9-80 months (mean 33 months). The MRM allowed detection of four otherwise occult malignancies. One of 11 cancer was missed on MRM due to benign appearance of enhancement. Compared with conventional methods MRM improved sensitivity (91 vs 64%) and specificity (90 vs 84%), respectively. This study suggests that additional MRM of the contralateral breast increases the diagnostic accuracy not only by enhancing the detection of second cancers but also by reducing false-positive results.

Evaluation of mammographic and clinical follow-up after 755 stereotactic vacuum-assisted breast biopsies.

PURPOSE: Stereotactic vacuum-assisted breast biopsy (VB) is a new method that promises high accuracy and reliability. In order to avoid surgery in cases with benign histology the examination must be quality assured and the accuracy should be well established. We present follow-up data of 755 VBs with benign results. METHODS: In all, 984 of 1268 consecutive VBs proved histopathologically benign (lobular carcinoma in situ and atypical ductal hyperplasia not included). Follow-up data are available for 755 of 984 (77%) lesions and constitute the basis of this evaluation. Follow-up mammograms were performed of 728 lesions at 6 to 67 months (mean 24, median 17.8) after VB. RESULTS: Seven technically unsuccessful cases underwent immediate rebiopsy; 3 unsuccessful cases were diagnosed otherwise. No false negative occurred among the 752 followed-up, eventually successful VBs. On follow-up mammography 444 of 728 (61%) benign lesions proved radiologically completely removed, 284 (39%) partially. In 6 cases (0.8%) a surgical biopsy was performed again during the follow-up time confirming the benign result. No scar was seen in 96%, a slight scar in 3.8%, and a small stellate scar with possible diagnostic interference in 0.3%. CONCLUSIONS: A benign diagnosis of quality assured VB is very reliable and leads to no or minimal scarring.